High throughput screening News and Research

RSS

High-throughput screening (HTS) allows scientists to test thousands of samples at once. These samples can be of a wide variety, and include, but are not limited to, amino acids, chemical compounds or cells.

Evotec and Genentech sign drug discovery deal

Evotec AG today announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group (SWX:RO) (SIX:ROG) (Pink Sheets:RHHBY), to discover novel small molecule therapeutics.

10 May 2010

CombinatoRx's synergistic drug combinations for cancer treatment to be highlighted at AACR 2010

CombinatoRx, Incorporated today announced that preclinical data on its discovery of novel synergistic drug combinations for the treatment of cancer will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

16 Apr 2010

Study on primary cilia formation may lead to new therapies for ciliopathies

A team of scientists at the University of California, San Diego School of Medicine have identified a network of genes that initiate and manage cilia formation. Although scientists have known about cilia for decades, only recently have they discovered their role in disease. This new discovery, which may lead to new therapies for ciliopathies, will appear in the April 15 edition of Nature.

16 Apr 2010

Universal screening test for CMV infection is not effective, says study

DNA analysis of dried blood samples routinely collected from newborns did not effectively identify an infection that is a major cause of hearing loss in children, according to a study in the April 14 issue of JAMA.

15 Apr 2010

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

“Glucocorticoids are a key component of combination therapy regimens in multiple myeloma and other hematological cancers. However, glucocorticoid use comes with substantial dose limiting toxicities. The ability to enhance glucocorticoid dependent effects while sparing associated toxicities may have important implications for the treatment of multiple myeloma and other B-cell malignancies”

15 Apr 2010

TD2, Horizon Discovery announce strategic alliance to advance personalized medicine

A strategic alliance announced today between TGen Drug Development (TD2) and Horizon Discovery Limited will significant advance personalized medicine.

13 Apr 2010

New series of filters screen compounds for drug development

The identification of compounds that could be promising candidates for drug development has become easier following research by the Walter and Eliza Hall Institute's medicinal chemistry group.

25 Mar 2010

Study: MetAP inhibitors prevent TB growth in test tubes

Suspecting that a particular protein in tuberculosis was likely to be vital to the bacteria's survival, Johns Hopkins scientists screened 175,000 small chemical compounds and identified a potent class of compounds that selectively slows down this protein's activity and, in a test tube, blocks TB growth, demonstrating that the protein is indeed a vulnerable target.

25 Mar 2010

Evotec, Active Biotech announce collaboration to identify small molecule modulators of priority biological target

Evotec AG today announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.

11 Mar 2010

Harvard University, Dana-Farber Cancer Institute complete major licensing agreement with Acetylon

Harvard University and Dana-Farber Cancer Institute announced today that they have concluded a major licensing agreement with Acetylon under which Harvard and Dana-Farber granted an exclusive therapeutic license to a robust platform technology and chemical methodology that enables high-throughput screening and lead optimization for HDAC inhibitor compounds.

9 Mar 2010

Axiogenesis, Lonza Cologne announce global distribution agreement

Axiogenesis AG has entered into a worldwide, exclusive distribution agreement with Lonza Cologne AG effective 01 January 2010. The agreement includes Axiogenesis’s current product and service portfolio, including the industry standard Cor.At® mouse embryonic stem cell-derived cardiomyocytes.

3 Mar 2010

UCSF, Genentech partner to discover and develop drug candidates for neurodegenerative diseases

The University of California, San Francisco has signed a partnership agreement with Genentech, Inc., a wholly owned member of the Roche Group, to discover and develop drug candidates for neurodegenerative diseases.

19 Feb 2010

TB's mechanism to evade body's immune system identified

Indiana University School of Medicine researchers have identified a mechanism used by the tuberculosis bacterium to evade the body's immune system and have identified a compound that blocks the bacterium's ability to survive in the host, which could lead to new drugs to treat tuberculosis.

16 Feb 2010

New bioanalytical methods have potential for investigative and screening applications

The Springer journal Analytical and Bioanalytical Chemistry (ABC) has chosen Jean-Philippe Frimat (29) as the recipient of its Best Paper Award 2009. Frimat is the lead author of a paper in ABC on plasma stencilling methods for cell patterning.

3 Feb 2010

Winner of ABC Best Paper Award 2009

2 Feb 2010

Senomyx launches sucrose enhancer that can reduce 50% of sugar usage

Senomyx is using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries. The Company’s flavor programs are focused on creating new ingredients that enhance sweet, savory, salty, and cooling tastes, as well as ingredients that reduce bitter taste. These new flavor ingredients include S6973, a unique sucrose enhancer that may be used to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.

30 Jan 2010

Labcyte introduces pre-calibrated liquid class packages for use with its Echo acoustic dispensers

Today Labcyte introduced two pre-calibrated liquid class packages for use with its award-winning Echo® acoustic dispensers and POD™ 810 plate assemblers, which move liquids with sound. This expanded capability will allow its high throughput screening customers to not only transfer compounds in DMSO, but enables the transfer of a wide range of liquids necessary to assemble miniaturized assays for biochemical and cell-based screening.

27 Jan 2010

Annelie Wendeberg presents protocol for identification of environmental microbes

Metagenomics, the study of DNA isolated from samples of naturally occurring microbial populations, is rapidly growing. Improvements to cloning and sequencing techniques are allowing researchers to study microorganisms in environmental samples, and new knowledge of species interactions and community dynamics is emerging.

5 Jan 2010

Scientists rediscover Cyclin G1 gene as prime target for anti-cancer therapies

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies.

16 Dec 2009

CombinatoRx presents encouraging results from its A2A and b2AR agonist programs for B-cell malignancies

CombinatoRx, Incorporated today announced that preclinical data from its Adenosine A2A receptor (A2A) and Beta-2 Adrenergic Receptor (b2AR) Agonist oncology programs demonstrated synergistic anti-cancer activity when combined with standard-of-care therapies in multiple myeloma and other B-cell malignancies.

8 Dec 2009

High throughput screening News and Research

Further Reading

Evotec and Genentech sign drug discovery deal

CombinatoRx's synergistic drug combinations for cancer treatment to be highlighted at AACR 2010

Study on primary cilia formation may lead to new therapies for ciliopathies

Universal screening test for CMV infection is not effective, says study

Synergistic interactions of A2A Agonist and PDE Inhibitors as adjunctive therapy to GC for treating MM

TD2, Horizon Discovery announce strategic alliance to advance personalized medicine

New series of filters screen compounds for drug development

Study: MetAP inhibitors prevent TB growth in test tubes

Evotec, Active Biotech announce collaboration to identify small molecule modulators of priority biological target

Harvard University, Dana-Farber Cancer Institute complete major licensing agreement with Acetylon

Axiogenesis, Lonza Cologne announce global distribution agreement

UCSF, Genentech partner to discover and develop drug candidates for neurodegenerative diseases

TB's mechanism to evade body's immune system identified

New bioanalytical methods have potential for investigative and screening applications

Winner of ABC Best Paper Award 2009

Senomyx launches sucrose enhancer that can reduce 50% of sugar usage

Labcyte introduces pre-calibrated liquid class packages for use with its Echo acoustic dispensers

Annelie Wendeberg presents protocol for identification of environmental microbes

Scientists rediscover Cyclin G1 gene as prime target for anti-cancer therapies

CombinatoRx presents encouraging results from its A2A and b2AR agonist programs for B-cell malignancies

Biochemical Assays for Efficient Hit Prioritization After Screening eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics